All News

undifferentiated,arthritis,early,RA

Second Efforts in Treating RA Partial Responders

d Jack Cush, MD

The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.

Read Article
awards.many_.jpg

ACR Announces 2022 Award Recipients

d ACR

The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals (ARP) proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation.

Read Article
pregnancy,embryo,fetal

Good Outcomes with TNF Blocker Use During RA Pregnancies

d Jack Cush, MD

A prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.

Read Article
morbidity,covid,heart,lung,brain

No Special Heart Risk With JAK Inhibitors, Study Finds

d MedPage Today

Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.

Read Article
infusion.biologic.jpg

Intravenous Immune Globulin in Dermatomyositis

d Jack Cush, MD

Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.

Read Article
Review of risk factors for osteoporosis and fractures in #RA. OP Risk factors same as gen population (but more prevalent in RA) - smoking, calcium intake, vit D deficiency, hypogonadism and chronic exposure to glucocorticoids https://t.co/KsE5ag29ZN https://t.co/OQtfoKcIX2

Links:

Dr. John Cush RheumNow ( View Tweet)
Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/gBWhjhS8Nu https://t.co/5799lleK22

Links:

Dr. John Cush RheumNow ( View Tweet)
Urine proteomics on 54 SLE pts in the Belimumab–Lupus Nephritis trial, compared responders (n 31) v non-responders (n 22), on BEL or SOC. Reduction in urinary CD163 was strongly associated with complete renal response @wk52 & CD23 @wk24 https://t.co/Rais8fKame https://t.co/F3B9W7u7VO

Links:

Dr. John Cush RheumNow ( View Tweet)
No Special Heart Risk With JAK Inhibitors, Study Finds Patients taking JAK inhibitors for RA experienced similar cardiovascular outcomes as those using the TNF blocker adalimumab (Humira), analysis of French national registry data indicated. https://t.co/oUt1hz88ll https://t.co/RkUUvfC4YK

Links:

Dr. John Cush RheumNow ( View Tweet)
Arthritis Clinical Trials Comparison Grid https://t.co/rLxTauJqX1 https://t.co/U7i5baSNwt

Links:

Dr. John Cush RheumNow ( View Tweet)
Sjogrens - Dx tips, myths & mistakes: • SS not rare; affects 1 in 400 • 95% female, but SS is more severe in men • African Americans have a severe systemic phenotype • Asians report dryness Sxs • Smoking & alcohol intake often avoided by SS pts https://t.co/B2hR7z8H5Z https://t.co/g0FKhcmoXa

Links:

Dr. John Cush RheumNow ( View Tweet)
Actual video of needle arthroscopy in patients w/ suspected septic arthritis. https://t.co/tWgP4ZpFBJ https://t.co/cLWM48NBlA

Links:

Dr. John Cush RheumNow ( View Tweet)
Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/XY5xQfY8Ba https://t.co/Cs3MUr7qIi

Links:

Dr. John Cush RheumNow ( View Tweet)
Large retrospective claims data analysis of 86 964 adults w/ severe obesity and NAFLD: comparing bariatric surgery (35%) to those with nonsurgical care. Bariatric surgery lowered the risk of CVD by 49% https://t.co/xEVVQVEX30 https://t.co/gSUIeH1K0k

Links:

Dr. John Cush RheumNow ( View Tweet)

2 HIV+ pts with HLH (MAS) successfully Rx w/ JAKi - ruxolitinib. Both had high fevers, severe pancytopenia, hypofibrinogenemia, hypertriglyceridemia, & increased ferritin, BMBx Hemophagocytosis, splenomegaly. https://t.co/yGs7e4Ftgp https://t.co/cv9NX31bZr

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR suggests a new ICD-10 code for "Pre-clinical RA".(PROPOSED NEW CODE: R76.81 “Abnormal rheumatoid arthritis-related immunologic findings without current or prior diagnosis of clinically apparent inflammatory arthritis.” This is not yet final. https://t.co/2Td0lYiUKg https://t.co/8m2OSfPWXz

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5 https://t.co/6fvjzGlMEY

Links:

Dr. John Cush RheumNow ( View Tweet)
Record a Question or Comment... Rheums: Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/rICbSJzPbk https://t.co/VIjlR6xlwQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib shows promise in scleroderma https://t.co/6qUGLlztBd https://t.co/Mk2x2HAkiO

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow. https://t.co/EGXslouPmC https://t.co/UVcdjzbxYp

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×